May 6, 2022 06:18 AM EDTUpdated 10:52 AM

With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

With Aduhelm in tat­ters, the search is on for Michel Vounatsos' re­place­ment at Bio­gen; David Liu, Roger Perl­mut­ter join in­sitro's SAB

Copy Chief

Editor

Sign up to read this article for free.

more like this

With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB